• Mukolitic therapy in childhood: opportunities, efficacy, safety

Mukolitic therapy in childhood: opportunities, efficacy, safety

SOVREMENNAYA PEDIATRIYA.2017.5(85):41-47; doi 10.15574/SP.2017.85.41

Kvashnina L. V.
SI «Institute of Pediatrics, Obstetrics and Gynecology of the National Academy of Medical Sciences of Ukraine», Kyiv

Data of mucolytic drugs using possibility in childhood are given in this article. There are mechanisms of forming and excretion of tracheobronchial secretions, the reasons of mucociliary clearance disorders discussed. The characteristics, basic modes of action, and recommendations on acetylcysteine usage are given.
Key words: children, mucociliary clearance, tracheobronchial secretions, mucolytic drugs, acetylcysteine.

References

1. Belousov YuB, Omelyanovskiy VV. (1996). Mukoliticheskie i fitoterapevticheskie sredstva. Klinicheskaya farmakologiya bolezney organov dyihaniya. Moskva, Universum Pablishing.

2. Gelle NA, Malahov AB. (1999). Mukoliticheskie i protivokashlevyie sredstva v praktike pediatra (lektsiya). Detskiy doktor. 4.

3. Golub AV. (2012). Bakterialnyie bioplenki — novaya tsel terapii? Klin mikrobiol antimikrob himioter. 14; 1: 23—29.

4. Delyagin VM, Byistrova NYu. (19990. Antibakterialnyie i mukoaktivnyie preparatyi. Moskva, Altus.

5. Zamotaev IP. (1993). Farmakoterapiya v pulmonologii. Moskva.

6. Kurashov OV, Trotsevich VA. (1992). Primenenie atsetiltsisteina v kompleksnom lechenii bolnyih s ostryimi otravleniyami 1,2-dihloretanom. Vracheb. delo. 10: 109—111.

7. Maidannyk VH, Smiian OI, Bynda TP. (2009). Hostra pnevmoniia u ditei: klinichni varianty perebihu, diahnostyka ta likuvannia. Sumy, SumDU: 156.

8. Mashkovskiy MD. (2008). Lekarstvennyie sredstva. Moskva, Novaya volna.

9. Mizernitskiy YuL. (2005). Printsipyi terapii ostryih respiratornyih infektsiy u detey. Pulmonologiya detskogo vozrasta: problemyi i resheniya. Moskva. 5: 106—111.

10. Mizernitskiy YuL, Ermakova IN. (2008). Sovremennyie mukoliticheskie i otharkivayuschie sredstva v terapii ostryih respiratornyih infektsiy u detey. Vestnik pediatrich farmakol i nutritsiol. 5; 4: 53—58.

11. Orlova AV, Gembitskaya TE. (1999). Bronhialnyiy sekret: obrazovanie, vyivedenie, izmenenie pod vliyaniem lekarstv. Allergiya. 4.

12. Popova EN, Kornev BM, Reznikova KU, Kondarova OV. (2005). Patogeneticheskoe i klinicheskoe obosnovanie primeneniya N-atsetiltsisteina (Fluimitsila) pri idiopaticheskom fibroziruyuschem alveolite. Pulmonologiya. 1: 34—41.

13. Popova EN, Arhipov DV, Kogan EA. (2004). Rol endotelialnoy disfunktsii i neoangiogeneza v razvitii pnevmoskleroza i legochnoy gipertenzii pri obyichnoy interstitsialnoy pnevmonii. Pulmonologiya. 3: 16—22.

14. Simonova OI, BorisYonok OA, Bushma KM. (2011). Mukolitiki dlya detey: slozhnyie voprosyi, vazhnyie otvetyi. Voprosyi sovr pediatrii. 10; 1.

15. Solopov VN. (2000). Astma. Kak vernut zdorove. Moskva, Meditsina.

16. Tatochenko VK. (2000). Prakticheskaya pulmonologiya detskogo vozrasta (spravochnik). Moskva.

17. Ushkalova EA. (2007). Farmateka. 17: 30—36.

18. Fedoseev GB, Zhiharev SS. (1989). Osnovnyie mehanizmyi zaschityi bronholegochnoy sistemyi. Bolezni organov dyihaniya. Pod red NV Putova. 1. Moskva, Meditsina: 112—143.

19. Tsaregorodtsev AD, Tabolin VA. (2002). Rukovodstvo po farmakoterapii v pediatrii i detskoy hirurgii. 1: Farmakoterapiya v pediatricheskoy pulmonologii. Pod red SYu Kaganova. Moskva, Medpraktika-M.

20. Chikina SYu. (2005). Primenenie Fluimitsila v respiratornoy meditsine. Atmosfera Pulmonologiya i allergologiya. 3: 36—40.

21. Chuchalin AG, Abrosimov VN. (2000). Kashel. Ryazan.

22. Al-Mazrou KA, Al-Khattaf AS. (2008). Adherent biofilms in adenotonsillar diseases in children. Arch Otolaryngol Head Neck Surg. 134: 20—3.

23. Andersen LW, Thiis J, Kharazmi A, Rygg I. (1995). Perfusion. 10; l: 21—26. https://doi.org/10.1177/026765919501000105

24. Aruoma OL, Haliiwell В, Ноеу ВМ, Bucler J. (1989). Free Radic Biol Med. 6; 6:.593—597. https://doi.org/10.1016/0891-5849(89)90066-X

25. Vu B, Chen M, Crawford RJ et al. (2009). Bacterial extracellular polysaccharides involved in biofilm formation. Molecules. 14: 2535—54.

26. Badawy A, State O, Abdelgawad S. (2007). N-Acetyl cysteine and clomiphene citrate for induction of ovulation in polycystic ovary syndrome: a crossover trial. Acta Obstet Gynecol Scand. 86(2): 218—222.

27. Berk M, Copolov D, Dean O et al. (2008). Biol Psychiatry. 64; 5: 361—368. https://doi.org/10.1016/j.biopsych.2008.04.022; https://doi.org/10.1016/j.biopsych.2008.03.004

28. Cohen M, Kofonow J, Nayak JV et al. (2009). Biofilm in chronic rhinosinusitis: a review. Am J Rhinol Allergy. 23: 255—60.

29. Biofilm life cycle. Montana State University Center for Biofilm Engineering. http://www.biofilm.montana.edu.

30. Boesgaard В, Aldershvile J, Pedersen F et al. (1991). J Cardiovas Pharmacol. 17; 6: 889—89. https://doi.org/10.1097/00005344-199106000-00005

31. Ceconi C, Curello S, Cargnoni A et al. (1988). J Mol Cell Cardiol. 20; 1: 5—13. https://doi.org/10.1016/S0022-2828(88)80174-3

32. Centers for Disease Control, California. (1997). Amanita phalloides Mushroom Poisoning. 46; 22: 489—492.

33. Cetinkale О, Senel О, Bulan R. (1999). Burns. 25; 2: 113—118. https://doi.org/10.1016/S0305-4179(98)00147-8; https://doi.org/10.1016/S0305-4179(98)00124-7

34. Foreman A, Psaltis AJ, Tan LW et al. (2009). Characterization of bacterial and fungal biofilms in chronic rhinosinusitis. Am J Rhinol Allergy. 23: 556—61.

35. De Flora S, Astengo M, Serra D, Bennicelli C. (1986). Cancer Lett. 32; 3: 235—241. https://doi.org/10.1016/0304-3835(86)90175-8

36. De Flora S, Grassi C, Carati L. (1997). Eur Respir J. 10: 1535—1541. https://doi.org/10.1183/09031936.97.10071535; PMid:9230243

37. Dekhuijzen PN. (2006). Ned Tijdschr Geneeskd. 150: 1222—1226.

38. Demedts M, Behr J, Buhl R et al. (2005). N Engl J Med. 353: 2229—2242. https://doi.org/10.1056/NEJMoa042976; PMid:16306520

39. Dickey DT, Muldoon LL, Doolittle ND et al. (2008). Cancer Chemother Pharmacol. 62; 2: 235—241. https://doi.org/10.1007/s00280-007-0597-2; PMid:17909806 PMCid:PMC2776068

40. Donlan RM, Costerton JW. (2002). Biofilms: survival mechanisms of clinically relevant microorganism. Clin Microbiol Rev. 15: 167—93.

41. Doroshow JH, Locker GY, Ifrim I, Myers CE. (1981). J Clin Invest. 68; 4: 1053—1064. https://doi.org/10.1172/JCI110328; PMid:7287901 PMCid:PMC370893

42. Droge W. (1993). Pharmacology. 46: 61—65.

43. Macchi A, Ardito F, Marchese A et al. (2006). Efficacy of N-acetylcisteine in combination with thiamphenicol in sequential (intramuscular/aerosol) therapy of upper respiratory tract infections even if sustained by bacterial biofilms. J Chemother. 18: 507—13.

44. Eylar Е, Rivera-Quinones С, Molina С et al. (1993). Immunology. 5; 1: 97—101.

45. Ferguson CL, Cantilena LRJr. (1992). J Toxicol Clin Toxicol. 3: 34—35.

46. Fiorentini С, Falzano L, Rivabene R et al. (1999). FEBS Lett. 453; 1—2: 124—128. https://doi.org/10.1016/S0014-5793(99)00706-1

47. Flemming HC, Wingender J. (2010). The biofilm matrix. Nat Rev Microbiol. 8: 623—33.

48. Gordon CA, Hodges N, Marriott C. (1991). Use of slime dispersants to promote antibiotic penetration through the extracellular polisaccaride of mucoid Pseudomonas aeruginosa. Antimicrob Agents Chemother. 35: 1258—60.

49. Hagiwara SI, Ishii Y, Kitamura S. (2000). Am J Respir Crit Care Med. 162; 1: 225—231. https://doi.org/10.1164/ajrccm.162.1.9903129; PMid:10903246

50. Horowitz JD, Antman EM, Lorell BH et al. (1983). Circulation. 68; 6: 1247—1253. https://doi.org/10.1161/01.CIR.68.6.1247

51. Hurd RW Wilder BJ, Helveston WR, Uthman BM. (1996). Neurology. 47; 5: 1264—1268.

52. Perez-Giraldo C, Rodriguez-Benito A, Moran FJ et al. (1997). Influence of N-acetylcysteine on formation of biofilm by Staphylococcus epidermidis. J Ant Chem. 39: 643—6.

53. Riise GC, Qvarfordt I, Larsson S et al. (2000). Inhibitory effect of N-acetylcysteine on adherence of Streptococcus pneumoniae and Haemophilus influenzae to human oropharyngeal epithelial cells in vitro. Respiration. 67: 552—8.

54. Kay J, Chow WH, Chan TM et al. (2003). JAMA. 289: 553—558. https://doi.org/10.1001/jama.289.5.553; https://doi.org/10.1121/1.1572368

55. Kilty SJ, Desrosiers MY. (2008). The role of bacterial biofilms and the pathophysiology of chronic rhinosinusitis. Curr Allergy Asthma Rep. 8: 227—33.

56. Kou-G, Shyu C, Jun-Jack C, Peiliang V. (2002). J Am Coll Cardiol. 40: 13831388.

57. Lindner Н, Holier Е, Erd В. et al. (1997). Blood. 89; 6: 1931—1938.

58. Marenzi G, Assanelli E, Marana I et al. (2006). N Engl J Med. 354: 2773—2782. https://doi.org/10.1056/NEJMoa054209; PMid:16807414

59. Mattin D, Willis S, Cline D. (1990). J Amer Board Fam Pract. 3: 293—296.

60. Menor С, Femandez-Moreno MD, Fueyo JA et al. (2004). J Pharm Exper Therap. 311: 668-676. https://doi.org/10.1124/jpet.104.069286; PMid:15226385

61. Morris PE, Bernard GR. (1994). Amer J Med Sci. 307: 119—127.

62. MoWus P, Cotgreave IA, Berggren M. (1986). Respiration. 50; 1: 31—42.

63. Olson KR. (1994). Poisoning & Drug Overdose. 2nd ed. Appleton & Lange.

64. Orhan G, Yapici N, Yuksel M et al. (2006). Heart and Vessels. 21; 1: 42-47. https://doi.org/10.1007/s00380-005-0873-1; PMid:16440148

65. Paul J. (2009). Millea N-Acetylcysteine: Multiple Clinical Applications. American Family Physician. 80; 3: 265—269.

66. Pintucci JP, Corno S, Garotta M. (2010). Biofilms and infections of the upper respiratory tract. Eur Rev Med Pharmacol Sci. 14: 683—90. PMid:20707288

67. Rizk AY, Bedaiwy MA, Al-Inany HG. (2005). N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resistant patients with polycystic ovary syndrome. Fertil Steril. 83(2): 367—370. https://doi.org/10.1016/j.fertnstert.2004.07.960; PMid:15705376

68. Roederer M, Staal FJ, Ela SW et al. (1993). Pharmacology. 46: 121—129. https://doi.org/10.1159/000139037; PMid:8441760

69. Shaikh ZA, Zaman К, Tang W, Vu T. (1999). Toxicol Lett. l04; l—2: 137—142. https://doi.org/10.1016/S0378-4274(98)00358-0; https://doi.org/10.1016/S0300-483X(99)00012-8

70. Stalenhoef A, Kroon AA, Demacker PN. (1991). Lancet. 337: 491. https://doi.org/10.1016/0140-6736(91)93425-9

71. Sucu N, Cinel I, Unlu A et al. (2004). Surgery Today. 34; 3: 237—242. https://doi.org/10.1007/s00595-003-2699-8; PMid:14999536

72. Tang LD. (1991). Brit J Pharmacol. 102; 3: 601—606. https://doi.org/10.1111/j.1476-5381.1991.tb12219.x; PMid:1364825 PMCid:PMC1917948

73. Tariq M, Morais C, Sobki S et al. (1999). Nephr Dialysis Transpl. 14: 4923—4929. https://doi.org/10.1093/ndt/14.4.923

74. Tepel M, Giet M, Schwarzfeld C et al. (2000). N Engl J M. 343: 180—184. https://doi.org/10.1056/NEJM200007203430304; PMid:10900277

75. Thakker DR, Yagi H, Levin W et al. (1985). Ed Anders MV. Bioactivation of foreign compounds: 177—230.

76. Winniford MD, Kennedy PL, Wells PJ, Hillis LD. (1986). Circulation. 73; 1: 138—142. https://doi.org/10.1161/01.CIR.73.4.662; https://doi.org/10.1161/01.CIR.73.1.138

77. Wispriyono В, Matsuoka М, Igisu Н, Matsuno K. (1998). J Pharmacol Exp Ther. 287; l: 344-351.

78. Yusof M, Yildiz D, Ercal N. (1999). Toxicol Lett. 106; 1: 41—47. https://doi.org/10.1016/S0378-4274(99)00014-4

79. Zhao T, Liu Y. (2010). N-acetylcysteine inhibit biofilm produced by Pseudomonas aeruginosa. BMC Microbiol. 10: 140. https://doi.org/10.1186/1471-2180-10-140; PMid:20462423 PMCid:PMC2882372